What is BrainQ?
Founded in 2011 and based in Israel, BrainQ is at the forefront of neuro-therapeutics, developing a novel platform designed to address neurological impairments. The company's core technology leverages a BCI-based approach, aiming to provide precision therapies for conditions affecting the brain. This strategic focus positions BrainQ within the rapidly evolving fields of medical technology, biotechnology, and artificial intelligence, targeting a critical unmet need in neurological treatment.
How much funding has BrainQ raised?
BrainQ has raised a total of $48.8M across 2 funding rounds:
Unspecified
$8.8M
Unspecified
$40M
Unspecified (2018): $8.8M with participation from Norma Investments, Amir Gross, OurCrowd.com, IT-Farm, and Qure Ventures
Unspecified (2021): $40M led by Hanaco, Dexcel Pharma Technologies, and Peregrine Ventures
Key Investors in BrainQ
Hanaco
Hanaco Ventures is a venture capital firm that supports founders with ambitious ideas, focusing on turning visions into successful businesses across various stages of growth. They are known for decisive action and collaboration with entrepreneurs.
Dexcel Pharma Technologies
Dexcel Pharma Technologies is involved in the pharmaceutical sector, likely contributing expertise and capital to companies developing therapeutic solutions.
Peregrine Ventures
Peregrine Ventures is dedicated to advancing medical innovation through strategic investments in life science companies, focusing on bringing groundbreaking healthcare technologies to market.
What's next for BrainQ?
The substantial enterprise-level backing and recent strategic investment indicate BrainQ's advanced stage of development and its potential for significant market impact. This capital infusion is expected to accelerate the company's research and development efforts, potentially enabling clinical trials, regulatory approvals, and the commercialization of its BCI-based therapies. BrainQ's trajectory suggests a move towards scaling operations and solidifying its position as a leader in precision neurology, with future growth likely dependent on successful clinical outcomes and market adoption.
See full BrainQ company page
